Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

36.31 +0.92 (+2.60%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 7, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	6,065,424
Open	35.61
Bid (Size)	36.30 (1,300)
Ask (Size)	36.31 (500)
Prev. Close	35.39
Today's Range	35.07 - 36.49
52wk Range	10.71 - 35.90
Shares Outstanding	692,072,184
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Could Roivant Sciences Be a Multibagger Stock Over the Next 5 Years? ↗

Today 6:35 EDT

Wall Street expects sales to soar as several commercial launches approach.

Via The Motley Fool

Roivant (ROIV) Q4 2025 Earnings Transcript ↗

May 20, 2026

Roivant (ROIV) Q4 2025 Earnings Transcript

Via The Motley Fool

Performance

YTD	+65.6%	+65.6%
1 Month	+27.4%	+27.4%
3 Month	+30.1%	+30.1%
6 Month	+70.5%	+70.5%
1 Year	+238.1%	+238.1%

More News

Roivant Sciences Q4 Earnings Call Highlights ↗

May 20, 2026

Via MarketBeat

ROIVANT SCIENCES LTD (NASDAQ:ROIV) Flashes Strong Breakout Setup with Near-Perfect Technical and Setup Quality Ratings ↗

May 14, 2026

Via Chartmill

Stay updated with the stocks that are on the move in today's pre-market session. ↗

May 20, 2026

Via Chartmill

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

May 20, 2026

From Roivant Sciences

Via GlobeNewswire

Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval ↗

May 18, 2026

Via The Motley Fool

Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? ↗

May 18, 2026

Via The Motley Fool

Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? ↗

May 18, 2026

Via The Motley Fool

Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares ↗

May 16, 2026

Via The Motley Fool

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026

May 11, 2026

From Roivant Sciences

Via GlobeNewswire

Roivant and Immunovant Solidify Market Leadership as Brepocitinib and FcRn Programs Hit Critical Clinical Milestones

April 02, 2026

Via MarketMinute

Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

April 02, 2026

From Roivant Sciences

Via GlobeNewswire

Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)

April 02, 2026

From Roivant Sciences

Via GlobeNewswire

New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

March 28, 2026

From Roivant Sciences

Via GlobeNewswire

A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you? ↗

March 15, 2026

Via The Motley Fool

Moderna Settles High-Stakes LNP Patent War with $2.25 Billion Agreement

March 05, 2026

Via MarketMinute

BlackBarn Capital Builds Warby Parker Stake as the Direct-to-Consumer Eyewear Leader Expands Nationwide ↗

March 04, 2026

Via The Motley Fool

Moderna-Arbutus-Genevant Patent Settlement: Wall Street Says Not Best-Case Scenario But Removes Overhang For MRNA Stock ↗

March 04, 2026

Via Stocktwits

MRNA Shares Rally After Hours On Inking Settlement Deal Over Vaccine Patent Row ↗

March 03, 2026

Via Stocktwits

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

March 03, 2026

From Arbutus Biopharma Corporation

Via GlobeNewswire

Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna

March 03, 2026

From Roivant Sciences

Via GlobeNewswire

Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis

March 03, 2026

From Roivant Sciences

Via GlobeNewswire

Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position ↗

February 22, 2026

Via The Motley Fool

Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction ↗

February 22, 2026

Via The Motley Fool

Frequently Asked Questions

Is Roivant Sciences Ltd. - Common Shares publicly traded?

Yes, Roivant Sciences Ltd. - Common Shares is publicly traded.

What exchange does Roivant Sciences Ltd. - Common Shares trade on?

Roivant Sciences Ltd. - Common Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Roivant Sciences Ltd. - Common Shares?

The ticker symbol for Roivant Sciences Ltd. - Common Shares is ROIV on the Nasdaq Stock Market

What is the current price of Roivant Sciences Ltd. - Common Shares?

The current price of Roivant Sciences Ltd. - Common Shares is 36.31

When was Roivant Sciences Ltd. - Common Shares last traded?

The last trade of Roivant Sciences Ltd. - Common Shares was at 07/07/26 04:00 PM ET

What is the market capitalization of Roivant Sciences Ltd. - Common Shares?

The market capitalization of Roivant Sciences Ltd. - Common Shares is 25.13B

How many shares of Roivant Sciences Ltd. - Common Shares are outstanding?

Roivant Sciences Ltd. - Common Shares has 25B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.